Navigasjon

  • Hopp til innhold
NTNU Hjemmeside NTNU Hjemmeside

ntnu.no

  • Studier
    • Studere på NTNU
    • Finn studieprogram
    • Søke opptak
    • Videreutdanning og deltid
    • Forkurs og oppfriskning
  • Studentliv
    • Student i Gjøvik
    • Student i Trondheim
    • Student i Ålesund
  • Forskning og innovasjon
    • Forskning
    • Innovasjon
    • Satsingsområder
    • Toppforskning
    • Ekspertlister
    • Ph.d.
  • Om NTNU
    • Fakulteter og institutter
    • Sentre
    • Bibliotek
    • Kart
    • Ledige stillinger
    • Arrangement
    • Nyheter
    • Kontakt oss
    • Om NTNU
  1. Ansatte

Språkvelger

English

Yan Baglo

Last ned pressefoto
Last ned pressefoto
Foto:

Yan Baglo

Forsker
Institutt for klinisk og molekylær medisin
Fakultet for medisin og helsevitenskap

yan.baglo@ntnu.no
Øya, Trondheim
Om Publikasjoner

Om

Ph.D. in Molecular Medicine, 2014.
Department of Cancer Research and Molecular Medicine, NTNU, Norway.

Postdoc 2015-2018

Wellman Center for Photomedicine at Harvard Medical School/Massachusetts General Hospital, Boston, USA

Postdoc 2018-2020

Fischell Department of Bioengineering at the University of Maryland, College Park, USA

 

Kompetanseord

  • NGS
  • cancer research
  • nanomedicine
  • photomedicine

Publikasjoner

Systematic Evaluation of Light-Activatable Biohybrids for Anti-Glioma Photodynamic Therapy

We prepared and characterized three well-defined photosensitizing biomolecules based on a clinically used photosensitizer, benzoporphyrin derivative (BPD).

Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy

We demonstrate that light-based photodynamic priming (PDP) coupled with vitamin D3 receptor (VDR) activation within fibroblasts increases intratumoral nanoliposomal irinotecan accumulation and suppresses protumorigenic CXCL12/CXCR7 crosstalk.

Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy

This study used the FDA-approved benzoporphyrin derivative (BPD) photosensitizer or its lipidated formulation ((16:0)LysoPC-BPD) to kill OVCAR-8 cells and reduce the likelihood that olaparib-resistant cells would have selective advantage.

Harnessing the Potential Synergistic Interplay Between Photosensitizer Dark Toxicity and Chemotherapy

Our study provides insights into the molecular alterations in two glioma lines caused by each monotherapy and the combinations, in order to inform the design of effective treatments.

Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells

We verify that P-gp, like ABCG2, plays a role in BPD transport and BPD-PDT resistance. Furthermore, we introduce porphyrin-lipid nanovesicles to escape P-gp and ABCG2-mediated efflux of BPD for improved PDT outcomes in two breast cancer cell lines.

Photoinactivation of Neisseria gonorrhoeae: A Paradigm-Changing Approach for Combating Antibiotic-Resistant Gonococcal Infection

Our findings indicated that antimicrobial blue light (aBL; wavelength, 405 nm) preferentially inactivated N. gonorrhoeae, including antibiotic-resistant strains, over human vaginal epithelial cells in vitro.

Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting

We developed a novel photoimmunoconjugate-nanoliposome comprising of three clinically used agents: anti-epidermal growth factor receptor monoclonal antibody cetuximab, benzoporphyrin derivative photosensitizer, and irinotecan chemotherapy.

Modulation of redox metabolism negates cancer-associated fibroblasts-induced treatment resistance in a heterotypic 3D culture platform of pancreatic cancer

In this study, a modular 3D culture model that comprised PDAC cells and patient-derived cancer-associated fibroblasts (CAFs) was developed to assess the effects of PDAC-CAF interactions on treatment efficacies.

Antimicrobial Blue Light Inactivation of Neisseria gonorrhoeae: Roles of Wavelength, Endogenous Photosensitizer, Oxygen, and Reactive Oxygen Species

The aim of this study was to investigate the efficacy, safety, and mechanism of action of antimicrobial blue light (aBL) for the inactivation of Neisseria gonorrhoeae, the etiological agent of gonorrhea.

Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery

In this study, we present preclinical evidence that a subtumoricidal photodynamic priming (PDP) strategy can relieve drug delivery barriers in the tumor microenvironment to safely widen the therapeutic window of a nanoformulated cytotoxic drug.

Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis

We show that the antibiotic minocycline, by its ability to minimize DNA repair via reduced expression of tyrosyl-DNA phosphodiesterase-1 (Tdp1), removes a key process attenuating the efficacy of irinotecan.
  • Kronologisk
  • Etter kategori
  • Alle publikasjoner i Nasjonalt vitenarkiv (NVA)

NTNU – Norges teknisk-naturvitenskapelige universitet

  • For ansatte
  • |
  • For studenter
  • |
  • Innsida
  • |
  • Blackboard

Studere

  • Om studier
  • Studieprogram
  • Emner
  • Videreutdanning
  • Karriere

Aktuelt

  • Nyheter
  • Arrangement
  • Jobbe ved NTNU

Om NTNU

  • Om NTNU
  • Bibliotek
  • Strategi
  • Forskning
  • Satsingsområder
  • Innovasjon
  • Organisasjonskart
  • Utdanningskvalitet

Kontakt

  • Kontakt oss
  • Finn ansatte
  • Spør en ekspert
  • Pressekontakter
  • Kart

NTNU i tre byer

  • NTNU i Gjøvik
  • NTNU i Trondheim
  • NTNU i Ålesund

Om nettstedet

  • Bruk av informasjonskapsler
  • Tilgjengelighetserklæring
  • Personvern
  • Ansvarlig redaktør
Facebook Instagram Linkedin Snapchat Tiktok Youtube
Logg inn
NTNU logo